Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacogenetics of ribavirin-induced anemia in HCV patients.

Pharmacogenomics - 1 Jun 2016

D'Avolio Antonio, Cusato Jessica, De Nicolò Amedeo, Allegra Sarah, Di Perri Giovanni

Abstract excerpt

Dual therapy (pegylated interferon plus ribavirin) was considered the standard of care for hepatitis C virus (HCV) treatment until 2011, when the first-wave direct-acting antivirals were added to this regimen for HCV genotype-1 patients to increase the sustained virological response rate. The second-wave direct-acting antivirals entered the clinical use also in some ribavirin (RBV)- and/or interferon-free...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anemia, Hemolytic
Share to Antiviral Agents
Share to Drug Monitoring

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Therapy, Combination

Share to Hepatitis C, Chronic

Share to Pharmacogenetics

Share to Pyrophosphatases

Share to Ribavirin

Source

Identifiers

PMID: 27248282
DOI: 10.2217/pgs.16.22

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacogenetics of ribavirin-induced anemia in HCV patients.PMID 27248282Read ↗

The role of pharmacogenetics in the treatment of chronic hepatitis C infection.Semantic proximity Read ↗

Clinical importance of pharmacogenetics in the treatment of hepatitis C virus infection.Semantic proximity Read ↗

Ribavirin in the treatment of chronic hepatitis C.Semantic proximity Read ↗

VDR gene polymorphisms impact on anemia at 2 weeks of anti-HCV therapy: a possible mechanism for early RBV-induced anemia.Semantic proximity Read ↗

Clinical milestones for the prediction of severe anemia by chronic hepatitis C patients receiving telaprevir-based triple therapy.Semantic proximity Read ↗

ITPA deficiency and ribavirin level are still predictive of anaemia in HCV-HIV-coinfected patients receiving ribavirin combined with a first-generation DAA (ANRS HC27 study).Semantic proximity Read ↗

Inosine triphosphatase polymorphisms and ribavirin pharmacokinetics as determinants of ribavirin-associate anemia in patients receiving standard anti-HCV treatment.Semantic proximity Read ↗

Estimated glomerular filtration rate but not solute carrier polymorphisms influences anemia in HIV-hepatitis C virus coinfected patients treated with boceprevir or telaprevir-based therapy.Semantic proximity Read ↗

Host genetic variants in the pathogenesis of hepatitis C.Semantic proximity Read ↗

Impact of ITPA gene polymorphism for predicting anemia and treatment outcome in HCV infected patients taking Sofosbuvir Ribavirin therapy.Semantic proximity Read ↗

Pharmacogenetics of hepatitis C: transition from interferon-based therapies to direct-acting antiviral agentsSemantic proximity Read ↗

Roles of ITPA and IL28B genotypes in chronic hepatitis C patients treated with peginterferon plus ribavirin.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.